Stock 600998 JOINTOWN PHARMACEUTICAL GROUP CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jointown Pharmaceutical Group Co., Ltd

Equities

600998

CNE100000W45

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
8.21 CNY 0.00% Intraday chart for Jointown Pharmaceutical Group Co., Ltd -3.86% +17.12%
Apr. 08 Jointown Pharmaceutical Sets Up Joint AI Lab with Peking University's Wuhan Campus MT
2023 Jiuzhoutong Pharmaceutical Investment Co., Ltd. announced that it expects to receive CNY 10.9100689 billion in funding from Jointown Pharmaceutical Group Co., Ltd CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 27,414 26,006 33,241 26,919 24,052 31,260 31,260 -
Enterprise Value (EV) 1 26,598 28,388 36,125 29,021 21,882 24,319 40,505 43,819
P/E ratio 20.3 x 15.4 x 11.7 x 11.6 x 12.2 x 12.7 x 11.4 x 9.59 x
Yield 0.68% - 2.75% 2.04% 3.83% 3.57% 4.06% 4.61%
Capitalization / Revenue 0.31 x 0.26 x 0.3 x 0.22 x 0.17 x 0.18 x 0.18 x 0.16 x
EV / Revenue 0.31 x 0.29 x 0.33 x 0.24 x 0.16 x 0.16 x 0.23 x 0.23 x
EV / EBITDA 11.7 x 10 x 7.36 x 6.93 x 6.21 x 6.5 x 7.48 x 7.04 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book 1.48 x 1.42 x 1.75 x 1.31 x 1.09 x 1.14 x 1.16 x 1.07 x
Nbr of stocks (in thousands) 3,916,806 3,833,850 3,818,311 3,814,733 3,847,610 3,807,514 3,807,514 -
Reference price 2 6.999 6.783 8.706 7.057 6.251 8.210 8.210 8.210
Announcement Date 4/25/19 4/28/20 4/26/21 4/25/22 4/24/23 4/26/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 87,136 99,497 110,860 122,407 140,424 150,140 173,844 192,368
EBITDA 1 2,266 2,838 4,909 4,187 3,526 3,741 5,416 6,224
EBIT 1 1,830 2,301 4,352 3,593 2,853 3,023 4,261 5,101
Operating Margin 2.1% 2.31% 3.93% 2.93% 2.03% 2.01% 2.45% 2.65%
Earnings before Tax (EBT) 1 1,831 2,317 4,334 3,363 2,838 2,991 3,856 4,605
Net income 1 1,341 1,727 3,075 2,448 2,085 2,174 2,809 3,348
Net margin 1.54% 1.74% 2.77% 2% 1.48% 1.45% 1.62% 1.74%
EPS 2 0.3452 0.4410 0.7430 0.6088 0.5129 0.5500 0.7203 0.8559
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 0.0479 - 0.2397 0.1438 0.2397 0.2500 0.3336 0.3788
Announcement Date 4/25/19 4/28/20 4/26/21 4/25/22 4/24/23 4/26/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - 35,776 34,293 41,151 44,581 51,439
EBITDA 1 - - - - - - - - - 835.6 1,132 1,323 1,418 1,608
EBIT 1 - - - - - - - - - 614.6 951.5 1,142 1,237 1,427
Operating Margin - - - - - - - - - 1.72% 2.77% 2.77% 2.77% 2.77%
Earnings before Tax (EBT) 1 - - - - - - - - - 618.7 771.5 925.8 1,003 1,157
Net income 1 - - - - - - - - - 350.4 587.4 704.8 763.6 881.1
Net margin - - - - - - - - - 0.98% 1.71% 1.71% 1.71% 1.71%
EPS 2 0.3500 0.0527 0.0192 0.1103 0.2061 0.1150 0.0815 0.1390 0.2000 0.1849 0.1600 0.2300 0.1900 0.2100
Dividend per Share - - - - - - - - - - - 0.3706 - -
Announcement Date 8/24/21 10/25/21 4/25/22 4/25/22 8/22/22 10/24/22 4/24/23 4/24/23 8/28/23 4/26/24 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - 2,381 2,884 2,102 - 7,100 9,245 12,560
Net Cash position 1 816 - - - 2,170 2,372 - -
Leverage (Debt/EBITDA) - 0.8391 x 0.5876 x 0.5021 x - 1.509 x 1.707 x 2.018 x
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) 7.19% 9.32% 15.9% 11.4% 8.98% 9.04% 10.4% 11.4%
ROA (Net income/ Total Assets) 2.26% 2.51% 4.05% 2.94% 2.34% 2.4% 2.5% 2.8%
Assets 1 59,370 68,924 75,984 83,379 89,104 100,589 112,350 119,566
Book Value Per Share 2 4.710 4.790 4.960 5.370 5.750 6.140 7.070 7.680
Cash Flow per Share 2 0.3100 0.7100 0.8800 0.8800 1.020 1.210 1.450 0.7300
Capex 1 1,815 1,175 1,158 1,215 1,083 885 1,389 1,509
Capex / Sales 2.08% 1.18% 1.04% 0.99% 0.77% 0.59% 0.8% 0.78%
Announcement Date 4/25/19 4/28/20 4/26/21 4/25/22 4/24/23 4/26/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Jointown Pharmaceutical Group Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
8.21 CNY
Average target price
10.18 CNY
Spread / Average Target
+24.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.31B
MCKESSON CORPORATION Stock McKesson Corporation
+17.35% 71.39B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.38% 8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.69% 8.19B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.96% 7.91B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.49% 4.54B
EBOS GROUP LIMITED Stock EBOS Group Limited
-3.38% 3.93B
GALENICA AG Stock Galenica AG
-2.61% 3.86B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+22.08% 3.64B
MEDIPAL HOLDINGS CORPORATION Stock MediPal Holdings Corporation
+7.96% 3.29B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 600998 Stock
  4. Financials Jointown Pharmaceutical Group Co., Ltd